Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-Fibrinolytic Drugs are used to prevent or reduce bleeding in patients who are at risk of excessive bleeding due to certain medical conditions or surgeries. Albania, a small country in the Balkans, has seen a steady growth in the Anti-Fibrinolytic Drugs market in recent years.
Customer preferences: Patients in Albania prefer Anti-Fibrinolytic Drugs that are effective and affordable. They are more likely to opt for generic versions of the drugs rather than branded ones. Additionally, they prefer drugs that have minimal side effects and are easy to administer.
Trends in the market: The Anti-Fibrinolytic Drugs market in Albania has seen a steady growth in recent years due to an increase in the number of surgeries being performed in the country. The rise in the number of surgeries has led to an increase in the demand for these drugs as they are used to prevent excessive bleeding during and after surgery. Additionally, there has been an increase in the number of patients with bleeding disorders, which has further contributed to the growth of the market.
Local special circumstances: Albania has a relatively small healthcare sector, which has led to a limited availability of healthcare services in the country. This has resulted in a higher demand for Anti-Fibrinolytic Drugs as patients prefer to prevent excessive bleeding rather than seek medical attention after the fact. Additionally, the country has a high incidence of thalassemia, a genetic blood disorder that can cause excessive bleeding, which has further contributed to the growth of the market.
Underlying macroeconomic factors: The Albanian economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has resulted in an increase in the availability of healthcare services and drugs in the country, including Anti-Fibrinolytic Drugs. Additionally, the Albanian government has been working to improve the healthcare sector in the country, which has further contributed to the growth of the market. However, the market is still relatively small compared to other countries in the region, which presents an opportunity for further growth in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
